Emerging Therapies in the Management of HR+, HER2- Metastatic Breast Cancer - Episode 1

An Overview of HR+, HER2- Metastatic Breast Cancer

,

Experts provides an overview of HR-positive , HER2-negative metastatic breast cancer and current treatment approaches.

Now Viewing
EP. 1: An Overview of HR+, HER2- Metastatic Breast Cancer
EP. 2: Overview of the Treatment Landscape for HR+, HER2- Advanced or Metastatic Breast Cancer
EP. 3: The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer
EP. 4: Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy
EP. 5: CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer
EP. 6: The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer
EP. 7: The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer
EP. 8: Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer
EP. 9: Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer

Related Content:

Emerging Therapies in the Management of HR+, HER2- Metastatic Breast CancerOncLive News Network®Breast Cancer
Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in Breast Cancer
Dr O’Regan on Sequencing Considerations in Advanced HR+ Breast Cancer
STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers